The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARα-positive acute promyelocytic leukemia: Results of a prospective trial

Haematologica

Volumn 91, Issue 5, 2006, Pages 671-674

  Lee, Seok ^a,b   Kim, Yoo Jin ^a   Eom, Ki Seong ^a   Min, Chang Ki ^a   Kim, Hee Je ^a   Cho, Seok Goo ^a   Lee, Jong Wook ^a   Min, Woo Sung ^a   Kim, Chun Choo ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Acute promyelocytic leukemia; Minimal residual disease; Real time quantitative polymerase chain reaction

Indexed keywords

IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID;

ACUTE LEUKEMIA; ADULT; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MALE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PROMYELOCYTIC LEUKEMIA; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION;

6-MERCAPTOPURINE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IDARUBICIN; KINETICS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LIFE TABLES; MALE; METHOTREXATE; MIDDLE AGED; MITOXANTRONE; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRETINOIN; TUMOR MARKERS, BIOLOGICAL;

EID: 33744500987     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021-8.
2. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T. Bernasconi C, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997;90:1014-21.
3. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999;93:4131-43.
4. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999;94:1192-200.
5. Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004;103:1237-43.
6. Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr. Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 2001;98:2651-6.
7. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-53.
8. Lo Coco F. Diverio D, Pandolfi PP, Biondi A, Rossi V. Avvisati G, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 1992;340:1437-8.
9. Miller WH Jr, Levine K. DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 1993;82:1689-94.
10. Diverio D, Pandolfi PP, Biondi A, Avvisati G, Petti MC, Mandelli F, et al. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 1993;85:3556-9.
11. Martinelli G, Remiddi C, Visani G, Farabegoli P, Testoni N, Zaccaria A, et al. Molecular analysis of PML-RAR· fusion mRNA detected by reverse transcription-polymerase chain reaction assay in long-term disease-free acute promyelocytic leukaemia patients. Br J Haematol 1995;90:966-8.
12. Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RARa and RARα-PML assessment in patients who ultimately relapse. Leukemia 1996;10:61-6.
13. Diverio D, Rossi V, Avvisati G. De Santis S, Pistilli A, Pane F, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood 1998;92:784-9.
14. Tobal K, Liu Yin JA. RT-PCR method with increased sensitivity shows persistence of PML-RARα fusion transcripts in patients in long-term remission of APL. Leukemia 1998;12:1349-54.
15. Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain JD, Fenaux P, et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000;14:324-8.
16. Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, et al. Quantitative real-time RT-PCR analysis of PML-RAR· mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003;101:2521-8.
17. Lee S, Kim DW, Cho B, Kim YJ, Kim YL, Hwang JY, et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003;120:145-53.
18. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005;105:3449-57.
19. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-9.
20. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187-220.